Latest Insider Transactions at Inhibrx Biosciences, Inc. (INXB)
This section provides a real-time view of insider transactions for Inhibrx Biosciences, Inc. (INXB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Inhibrx Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Inhibrx Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
37,500
+21.16%
|
$525,000
$14.19 P/Share
|
|
Nov 19
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
69,686
+40.55%
|
$975,604
$14.23 P/Share
|
|
Oct 03
2024
|
Kristiina Md Vuori Director |
BUY
Open market or private purchase
|
Direct |
6,667
+24.59%
|
$100,005
$15.0 P/Share
|
|
Sep 16
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
13,037
+1.81%
|
$221,629
$17.13 P/Share
|
|
Sep 12
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
26,963
+3.75%
|
$404,445
$15.05 P/Share
|
|
Sep 11
2024
|
Kristiina Md Vuori Director |
BUY
Open market or private purchase
|
Direct |
6,457
+31.91%
|
$96,855
$15.07 P/Share
|
|
Sep 10
2024
|
Kristiina Md Vuori Director |
BUY
Open market or private purchase
|
Direct |
179
+2.39%
|
$2,685
$15.0 P/Share
|
|
Sep 10
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
8,500
+1.26%
|
$127,500
$15.19 P/Share
|
|
Sep 09
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
9,500
+1.43%
|
$142,500
$15.21 P/Share
|
|
Sep 06
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
26,000
+3.86%
|
$390,000
$15.29 P/Share
|
|
Sep 03
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
20,000
+5.74%
|
$300,000
$15.99 P/Share
|
|
Aug 30
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+6.45%
|
$140,000
$14.02 P/Share
|
|
Aug 29
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+6.9%
|
$140,000
$14.03 P/Share
|
|
Aug 29
2024
|
Kristiina Md Vuori Director |
BUY
Open market or private purchase
|
Direct |
7,140
+50.0%
|
$99,960
$14.0 P/Share
|
|
Aug 28
2024
|
Kimberly Manhard Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$130,000
$13.98 P/Share
|
|
Aug 23
2024
|
Douglas Forsyth Director |
BUY
Open market or private purchase
|
Indirect |
59,812
+21.03%
|
$837,368
$14.07 P/Share
|
|
Aug 22
2024
|
Douglas Forsyth Director |
BUY
Open market or private purchase
|
Indirect |
15,188
+8.44%
|
$182,256
$12.89 P/Share
|
|
Aug 21
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
12,945
+19.09%
|
$155,340
$12.93 P/Share
|
|
Aug 20
2024
|
Mark Lappe Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
27,055
+39.22%
|
$324,660
$12.97 P/Share
|
|
Jun 24
2024
|
Jon Faiz Kayyem Director |
BUY
Bona fide gift
|
Indirect |
20,000
+38.1%
|
-
|
|
Jun 24
2024
|
Jon Faiz Kayyem Director |
SELL
Bona fide gift
|
Indirect |
89,050
-7.74%
|
-
|
|
Jun 05
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
57,549
+2.42%
|
$978,333
$17.56 P/Share
|
|
Jun 04
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
89,063
+3.94%
|
$1,514,071
$17.84 P/Share
|
|
Jun 03
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
127,530
+6.13%
|
$2,168,010
$17.26 P/Share
|
|
May 31
2024
|
Jon Faiz Kayyem Director |
BUY
Open market or private purchase
|
Indirect |
70,193
+7.42%
|
$1,123,088
$16.14 P/Share
|
|
May 29
2024
|
Inhibrx, Inc. |
SELL
Other acquisition or disposition
|
Direct |
13,316,140
-92.0%
|
-
|
|
May 29
2024
|
Brendan P. Eckelman Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
513,888
+50.0%
|
-
|
|
May 29
2024
|
Douglas Forsyth Director |
BUY
Grant, award, or other acquisition
|
Indirect |
149,564
+50.0%
|
-
|
|
May 29
2024
|
Jon Faiz Kayyem Director |
BUY
Grant, award, or other acquisition
|
Indirect |
818,575
+50.0%
|
-
|
|
May 29
2024
|
Mark Lappe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
761,413
+50.0%
|
-
|